On January 12, EP Global (PINK:EPGL) issued a press release announcing that the company has "resumed discussions with medical schools, rehabilitation facilities and clinics in Argentina and Chile who have expressed interest in EP Digital, the electronic version of EP's flagship publication." This opens up the opportunity for EP to expand into a Spanish language version.

Epanding EP to include a Spanish language version not only enables EP Global to reach out to Chile and Argentina, but to other Spanish speaking countries throughout the world and to Spanish speaking facilities and families in the United States. There are at least twenty-one countries throughout the world where Spanish is spoken. That means that by providing a Spanish language version of EP, there are at least twenty-one new opportunities open to EP Global. Those countries are: Mexico, Cuba, Dominican Republic, Puerto Rico, Spain, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Argentina, Bolivia, Chile, Columbia, Ecuador, Paraguay, Peru, Uruguay, and Venezuela.

The company also announced that it has begun exploratory discussions with several companies in the nutraceutical market. Joe Valenzano, the CEO for EP Global, explained that "EPGL is uniquely positioned to review, evaluate, and present excellent information on these products and their efficacy and safety as well as interactions and possible contraindications with Rx medications."

With the constant and ever-growing concerns for people to develop healthier dietary habits, to become better physically fit, and to use more natural alternatives to costly pharmaceuticals often-times having a multitude of negative side effects, the management of EP Global is wise to give serious consideration towards including quality information about nutraceutical products in its publications. Not only will doing so contribute additional valuable content for the publications, but it will also contribute towards expanding the market-base for the publications.

At the current time, EP Global is also considering convening a special shareholders meeting in February for the purpose of asking the shareholders to increase the number of authorized shares from 2 billion to 5 billion. According to company management, the additional shares would be used for the paying down of outstanding debts that it owes and for the realization of the company's "vision" for expansion.

Shareholders and investors are beginning to realize that in increasing the authorized shares, the float for the company will increase as the authorized shares are sold into the market. This would have the effect of reducing the volatility for the stock's share price and slowing down price movements within the market, which is never a good thing for shareholders.

Uncertainties surrounding the pending vote on the increase in authorized shares has played a significant role in reducing volume for the trading of the company's stock and keeping the share price low. There are many shareholders that believe that they will be able to defeat the proposed increase when they do vote on the matter at the special shareholders meeting in February. It is also the belief of many shareholders that once the issue is defeated, trading volume will resume and escalate for the stock, driving the share price back upwards.

As for the payment of the debt owed by the company, some shareholders maintain a position that it would be more beneficial to the image and reputation of the company if management were to pay those debts using revenue generated by the normal day-to-day operations of the company. From the looks of things to the shareholders, this is entirely possible.

The company has announced that it will be in receipt of a government grant in the immediate future, the amount of which comes to $640,000, and that it is entertaining the possibility of selling select nutraceutical products from its online portals. All of this, coupled with the revenue that the company generates through sales and subscription sales of its publications, advertising revenue generated by companies advertising in the publications and in the company's online portals, the sales of books published by the company, and its many other streams of revenue becomes convincing to many shareholders that the company can and will be able to meet its financial obligations without dilution of shares and detriment to its shareholders.

The author of this blog did not receive payment for writing this article. The author does hold shares in the company, EPGL.

Tags: EPGL

Bookmark: